On September 7, the 41st China Pharmaceutical Industry Information Annual Conference 2024 and the "2023 Top 100 Chinese Pharmaceutical Enterprises List Release Ceremony" were held in Chengdu. During the event, the "2023 Top 100 Chinese Pharmaceutical Enterprises List" was announced, with Jiangsu JumpCan Holding Group ranking 33rd, moving up two places from the previous year.
The China Pharmaceutical Industry Information Annual Conference is a bellwether for gauging the development trends of China's pharmaceutical industry, hosted by the China National Pharmaceutical Industry Information Center. The Top 100 Chinese Pharmaceutical Enterprises List is one of the most authoritative and representative industry selection activities in China. In the context of ongoing domestic and international pharmaceutical industry transformations, the listed enterprises fully demonstrate exceptional resilience and innovative development capabilities.
In recent years, JumpCan Pharmaceutical has swiftly adapted to changes in the pharmaceutical landscape, driven by innovation and embracing transformation. In 2023, the company achieved stable and positive operating results, with revenue reaching RMB 9.655 billion. Net profit attributable to shareholders of the listed company was RMB 2.823 billion, a year-on-year increase of 30.04%, while net profit after deducting non-recurring gains and losses was RMB 2.692 billion, up 32.72% year-on-year. This year, JumpCan Pharmaceutical also ranked 8th in the "2023 Top 100 Chinese Traditional Chinese Medicine Enterprises" list, reflecting the company's growing strength and brand influence.
Innovation in R&D is a core element for developing new quality productive forces and the "driving source" of corporate development. JumpCan Pharmaceutical has continuously increased its innovation efforts, with cumulative R&D investment exceeding RMB 1.5 billion over the past three years. In 2023, the company obtained drug registration certificates for Sodium Valproate Concentrated Solution for Injection (Jikening), Azithromycin for Suspension (Shuluokang) , Pregabalin Oral Solution (JumpCan Ruining), Atomoxetine Hydrochloride Oral Solution (Tongjing), Esmolol Hydrochloride Injection (Luoketuo), Ibuprofen Suspension (JumpCan Tongtai), and Xiao'er Chiqiao Qingre Syrup (K-tonpei). In 2024, the company has already received drug registration certificates for Fexofenadine Hydrochloride for Suspension (Minfeile), Levofloxacin and Sodium Chloride Injection, and Lafutidine Tablets. The active pharmaceutical ingredient Rabeprazole Sodium has been approved, while Pranlukast Hydrate and Lidocaine Cataplasms have completed registration applications. The company has obtained one patent authorization in China and one in Europe. JumpCan Pharmaceutical continues to strive to provide patients with high-quality medicines that offer better value, making healthcare more accessible.
JumpCan Pharmaceutical inherits and innovates in traditional Chinese medicine (TCM) while deeply investing in innovative drugs, continuously achieving R&D outcomes with high technological barriers and high clinical value. The company approved China's first Fexofenadine Hydrochloride for Suspension, and Xiao'er Chiqiao Qingre Syrup (K-tonpei) is the first improved TCM new drug launched since the implementation of the new Drug Registration Management Measures. Additionally, the project "Research Model for Classical Prescription Categories and Key Technologies with Application in Regularity Discovery of Traditional Chinese Medicine Incompatibility", carried out by JumpCan Pharmaceutical, won the Second Prize of the 2023 National Science and Technology Progress Award. This project established the first early-warning system platform for combined use of Chinese medicines domestically and internationally, providing researchers with over 10,000 professional inquiries and safety warnings to support safe and effective clinical medication.
Aligning with its medium-to-long-term development strategy and market demands, JumpCan Pharmaceutical enables expansive growth through business development. While deepening in-house R&D, the company has introduced biologics and innovative drugs such as long-acting recombinant human growth hormone, oral PDE4 (phosphodiesterase 4) inhibitor, drug-targeted digestive protease inhibitor, and the polymerase acidic protein (PA) inhibitor Maseloxavir for treating or preventing influenza. Maseloxavir is a new-generation PA endonuclease inhibitor with broad-spectrum antiviral properties, and its New Drug Application (NDA) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). JumpCan Pharmaceutical has achieved a dual-drive model of independent R&D and collaborative development, striving to meet patients' evolving and diverse medication needs.